Pernix Therapeutics (PTX) Announces Quarterly Earnings Results

Pernix Therapeutics (NASDAQ:PTX) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.89) EPS for the quarter, Morningstar.com reports. The company had revenue of $37.16 million for the quarter.

PTX stock traded down $0.13 during trading on Friday, hitting $0.69. 294,354 shares of the stock traded hands, compared to its average volume of 130,048. Pernix Therapeutics has a 1 year low of $0.59 and a 1 year high of $3.30.

Separately, ValuEngine raised shares of Pernix Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, August 20th.

TRADEMARK VIOLATION WARNING: “Pernix Therapeutics (PTX) Announces Quarterly Earnings Results” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/11/10/pernix-therapeutics-ptx-announces-quarterly-earnings-results.html.

Pernix Therapeutics Company Profile

Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.

Further Reading: Technical Analysis of Stocks, How Can It Help

Earnings History for Pernix Therapeutics (NASDAQ:PTX)

Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply